FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Subscribe To Our Newsletter & Stay Updated